Chemotherapy Protocol for PCNSL with Rituximab
The MATRix regimen (high-dose methotrexate, high-dose cytarabine, rituximab, and thiotepa) is the recommended rituximab-containing protocol for newly diagnosed PCNSL in eligible patients, demonstrating superior survival outcomes with a 7-year overall survival of 56% and progression-free survival of 52%. 1
MATRix Regimen Details
The MATRix protocol consists of:
- High-dose methotrexate (HD-MTX): Minimum 3 g/m² delivered over 3 hours (some experts use 500 mg/m² bolus over 15 minutes followed by the remainder)
- High-dose cytarabine (HD-AraC): 2 g/m² every 12 hours for 2 days
- Rituximab: 375 mg/m² (standard dosing)
- Thiotepa: Added to the combination (specific dosing per protocol)
This regimen is administered for 4 cycles as induction therapy 1.
Patient Eligibility
MATRix is appropriate for patients:
- Age ≤65 years with ECOG performance status 0-3, OR
- Age ≤70 years with ECOG performance status ≤2 1
Expected Outcomes
The IELSG32 trial demonstrated that MATRix achieved:
- 7-year PFS: 52% (vs. 29% with rituximab-HD-MTX-HD-AraC alone, vs. 20% with HD-MTX-HD-AraC)
- 7-year OS: 56% (vs. 37% vs. 26% respectively)
- When followed by consolidation (ASCT or WBRT): 7-year OS of 70% 1
Real-world data from 156 patients across UK, Italy, and Germany confirmed comparable efficacy with 2-year OS of 64%, though only 62% completed all 4 cycles and three-quarters required dose reductions 1.
Alternative Rituximab-Containing Regimens
If MATRix is not feasible, other evidence-based options include:
R-MBVP (Rituximab-Methotrexate-Carmustine-Etoposide-Methylprednisolone)
- Two cycles of R-MBVP followed by HD-AraC
- 3-year OS: 61% in the HOVON 105 trial
- Important caveat: This trial showed NO event-free survival advantage with rituximab addition 1, 2
R-MPV (Rituximab-Methotrexate-Procarbazine-Vincristine)
- Listed as acceptable alternative in guidelines
- Specific outcomes detailed in supplementary materials 1
R-MT (Rituximab-Methotrexate-Temozolomide)
- Option for patients unable to tolerate more intensive regimens
- Listed in guideline-approved regimens 1
Critical Caveats About Rituximab in PCNSL
The benefit of rituximab in PCNSL remains controversial 1:
Not FDA or EMA approved for PCNSL indication 1
Conflicting evidence: The HOVON 105-ALLG NHL 24 randomized trial (200 patients) found NO event-free survival advantage when rituximab was added to MBVP chemotherapy 1, 2
Blood-brain barrier concerns: The large rituximab molecule has limited CNS penetration, which theoretically limits efficacy 2
Guidelines state: "The balance between tolerability and efficacy should be discussed with patients and their carers" 1
Despite these concerns, MATRix (which includes rituximab) demonstrated superior outcomes compared to regimens without rituximab in the IELSG32 trial, though this may be attributable to the thiotepa component rather than rituximab 1.
Consolidation Strategy
After induction with MATRix or alternative regimen:
For patients <60-65 years with responsive disease:
- Autologous stem cell transplantation (ASCT) is preferred consolidation
- Thiotepa-based conditioning regimens recommended
- 8-year OS: 69% after ASCT 1
For older patients or those ineligible for ASCT:
- Reduced-dose WBRT (23.4 Gy) may be considered
- Standard-dose WBRT (36-40 Gy) should be avoided in elderly due to severe neurocognitive toxicity 1
Monitoring During Treatment
- MRI brain with gadolinium: Every 2 cycles during induction, then 2 months post-consolidation
- CSF and ocular exams: If involved at baseline 1
- Response assessment: Use International PCNSL Collaborative Group (IPCG) criteria 1
Practical Considerations
Dose adjustments: Three-quarters of real-world MATRix patients required dose reductions, particularly important in patients >70 years, ECOG PS 3, or significant comorbidities 1. Judicious MTX dose reduction based on renal function is recommended 1.
Treatment-related mortality: 6% with MATRix in real-world setting 1